Egetis Therapeutics

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

Regulatory

January 18, 2022

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

January 11, 2022

Egetis Therapeutics gets Notice of Intent to Grant for a new European patent for a combination therapy with Aladote

Regulatory

December 13, 2021

Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data

Upcoming event

February 17

Year end report for 2021

Latest presentation

January 22, 2022

Egetis' Corporate Presentation

Latest Report

November 4, 2021

Interim report Q3, 2021

March 30, 2021

Annual report 2020 (in Swedish)

Calendar and upcoming reports

February 17, 2022

Year-end-report

March 15-17

Carnegie Healthcare Seminar

April 26, 2022

Interim report January - March

May 10, 2022

Annual General Meeting

August 19, 2022

Half-year report January - June

November 8, 2022

Interim report January - September

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com